by rss feed | Sep 12, 2026 | News Feeds
An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5 mg/kg dose for evaluation in the...
by rss feed | Sep 12, 2026 | News Feeds
The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according to first clinical data from the ongoing Phase...
by rss feed | Sep 12, 2026 | News Feeds
New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows that, in people living with diabetes (type 1 or 2) using data from continuous glucose monitoring (CGM) devices...
by rss feed | Sep 12, 2026 | News Feeds
Scientists identified a new vision condition linked to a gene already connected to a different vision-loss disease. While the previously identified disease causes loss of central vision, the new condition affects peripheral and night vision. Read Original...
by rss feed | Sep 12, 2026 | News Feeds
What makes the brain fall asleep? For nearly a century, scientists have looked to structures deep within the brain for the answer. Read Original...
by rss feed | Sep 12, 2026 | News Feeds
The U.S. Food and Drug Administration this week granted permission for investigators at the University of Colorado Anschutz to conduct a clinical trial testing genetically engineered immune cells in adults with advanced colorectal cancer and pediatric patients with...
